

ASX Release

European Anagrelide Cancer Patent

- **Anagrelide is an FDA approved drug for blood disorders**
- **Strong scientific rationale for its use in cancer**
- **SUDA has global IP rights across multiple delivery systems**
- **EU patent office notice to grant anagrelide patent**
- **Plans to advance into Phase 1 cancer clinical trials underway**

PERTH, AUSTRALIA – 22 July 2019: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, is pleased to announce that the European Patent Office has informed SUDA that it intends to grant our anagrelide Patent.

The European Patent Office will grant SUDA's Application No. 15817516.6 titled "Use of Anagrelide for Treating Cancer". The patent has an expiry date of December 2035.

The granting of this patent is a very important step in the commercialisation process for SUDA and validates our position as the only company in the world with a patent covering the use of anagrelide in the treatment or prevention of metastatic disease in the bone or lung in a patient with a high platelet count and a solid cancers including brain, oral cavity, head and neck, thyroid, gastrointestinal, pancreatic, liver, kidney, colorectal, lungs and bronchus, ovaries, endometrium, cervix, breast prostate, skin, mesothelioma, melanoma, gall bladder and multiple myeloma.

The patent covers very broad routes of administration beyond SUDA's proprietary oro-mucosal and hydrotrope technologies, including transdermal patches and creams lotions and gels, and injectable formulations.

To bring the importance of this patent into perspective it is imperative to understand the role of platelets in cancer progression and overall survival of cancer patients.

Besides the critical functions that platelets have in controlling the clotting process and wound healing, platelets have been increasingly identified as active players in a number of processes that support cancer. Once activated by the cancer cells, platelets provide the chemicals to assist the primary tumour to generate its own blood supply and subsequently protect released cancer cells as they move around the body and form new tumours.

Once the platelets are activated by the cancer cells, they release many different bio-active materials into the blood stream. The cancer cells understand the importance of the role of platelets in supporting their growth and spread and they send out chemicals to the body to produce more platelets. The more platelets the body produces the shorter the overall survival of the patient.

There is considerable evidence now presented in the scientific community that confirms that if we can reduce the platelet count then we can improve outcomes for cancer patients.

Anagrelide is the only approved medicine that works specifically on reducing platelets without affecting any other blood cells and SUDA has the patent for its use in cancer.

SUDA's Chairman Paul Hopper said: "This is a very important step in our anagrelide program. A strong patent position is critical for extracting the maximum value for a project in our industry, and to be informed of the intent to grant the European patent is a significant value creation point for the company."



Further information:

STEPHEN CARTER

CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR

SUDA Pharmaceuticals Ltd

Tel: +61 8 6142 555

sjcarter@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of: migraine headache; chemotherapy-induced nausea and vomiting; erectile dysfunction; PAH; epileptic seizures and pre-procedural anxiety; and cancer. For more information, visit www.sudapharma.com